ARCHIVES

Highlights of NCDDGs: 3 Drugs on Market, 12 in Development; Advisors Approve Plan to Issue $10.5 Million Contract For Pediatric Preclinical Testing Program

This article is from The Cancer Letter archive.

Vol. 28 No. 44 | November 29, 2002

Download PDF Visit The Full Archive

Related Articles

New Technology May Enable Therapy Tailored To Patient’s Predicted Response

April 26, 2002

Pharmacia Says SU5416 Doesn’t Benefit Colorectal Cancer Patients, Closes Trial.

March 1, 2002

Chabner Criticizes FDA Crackdown On Off-Label Info

June 28, 1991

Neutron Therapy Contracts Wind Down Next Year; DCT To Consider Whether To Continue Support

March 25, 1988

Dramatic Increase In Third World Cancer Rates May Face National, International Organizations: Murphy

September 17, 1982

Panel Urges Research On DCIS To Identify Women At High Risk For Invasive Cancer

September 25, 2009